Roche to seize leap-frog opportunity in lung cancer

LONDON (Reuters) – After lagging rivals in cancer immunotherapies, Swiss drugmaker Roche hopes to leap-frog into the lead in the biggest market, tackling previously untreated lung cancer.

This post was syndicated from Reuters: Health News. Click here to read the full text on the original website.

Be the first to comment

Leave a Reply